- Title
- 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
- Creators
- B. Pothuri - Gynecologic Oncology GroupS. Han - KU LeuvenD. Chase - Arizona OncologyF. Heitz - Kliniken Essen-MitteR. Burger - University of PennsylvaniaL. Gaba - Hospital Clínic de BarcelonaL. Van Le - University of North Carolina at Chapel HillE. Guerra - Medical Oncology Department, Breast and Gynecological Cancer Unit, Hospital Ramon y Cajal, Madrid, SpainD. Bender - University of IowaJ. Korach - Sheba Medical CenterN.G. Cloven - Texas OncologyP. Follana - Centre Antoine LacassagneJ-F. Baurain - Cliniques Universitaires Saint-LucC. Pisano - Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"U. Peen - Herlev HospitalJ. Maenpaa - Tampere University HospitalE. Bacqué - GlaxoSmithKlineY. Li - GlaxoSmithKlineA. González Martín - Clinica Universidad de NavarraB.J. Monk - The US Oncology Network
- Publication Details
- Annals of oncology, Vol.31, pp.S612-S613
- Publisher
- Elsevier Ltd
- Identifiers
- 991005969037002656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of oncology, Vol.31, pp.S612-S613
09/2020
Metrics
4 Record Views